论文部分内容阅读
目的：在研究中药血府逐瘀汤方抗肝纤维化的基础上，进一步比较中药血府逐瘀汤方和秋水仙碱对实验性肝硬化大鼠门脉高压的作用的强度和特点。方法：选用ＳＤ大鼠作为实验材料，用ＣＣｌ４诱导肝硬化，按随机原则分为正常对照组，血府逐瘀汤方组，秋水仙碱组和肝硬化模型组。于实验１３周处死动物直接测定门脉压，取肝组织观察肝纤维化程度。结果：血府逐瘀汤方平均门脉压为１３８±０２７Ｋｐａ，秋水仙碱组为１６９±００８Ｋｐａ均明显低于肝硬化模型组１９１±０１７Ｋｐａ（Ｐ＜００１），门脉高压形成率两者亦显著低于肝硬化模型组（２／１０ｖｓ９／１０，１０／１０Ｐ＜００１），但中药血府逐瘀汤方组肝硬化程度明显轻于秋水仙碱组（Ｐ＜００１）。结论：中药血府逐瘀汤方与秋水仙碱长期使用具有显著的抗门脉高压形成作用，但两者降低门脉高压作用效果有显著区别。血府逐瘀汤方在阻断或延缓肝纤维化和门脉高压形成方面明显优于秋水仙碱，中药血府逐瘀汤方较秋水仙碱在阻断或延缓门脉高压形成上具有更好的应用前景。
Objective: To study the anti-hepatofibrosis effect of Xuefu Zhuyu Decoction of traditional Chinese medicine, and further compare the intensity and characteristics of the effects of Xuefu Zhuyu Decoction and Colchicine on the portal hypertension in experimental liver cirrhosis rats. Methods: SD rats were used as experimental materials. Cirrhosis induced by CCl4 was divided into normal control group, Xuefu Zhuyu Decoction group, colchicine group and cirrhosis model group according to the random principle. At the 13th week of the experiment, the animals were sacrificed and the portal pressure was measured directly. The liver tissue was taken to observe the degree of hepatic fibrosis. Results: The mean portal pressure of Xuefu Zhuyu Tangfang was 138±027Kpa, and that of colchicine group was 169±008Kpa, which was significantly lower than that of cirrhotic model group 191±017Kpa (P <001), portal hypertension formation rate was also significantly lower than the cirrhosis model group (2/10vs9/10, 10/10P < 0 01), but the degree of liver cirrhosis was obvious in the Xuefu Zhuyu Tang recipe group Lighter than colchicine group (P<001). Conclusion: The long-term use of Xuefu Zhuyu Tang and Colchicine has a significant effect on the formation of portal hypertension, but there is a significant difference in the effect of reducing portal hypertension. Xuefu Zhuyu Decoction is better than colchicine in blocking or delaying the formation of hepatic fibrosis and portal hypertension. Xuefu Zhuyu Decoction is more effective than colchicine in blocking or delaying the formation of portal hypertension. Good application prospects.